Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.
Participants with and without T2D will undergo 2 days of forearm immobilization as a model of local physical inactivity. Before, throughout, and after immobilization arteriovenous forearm balance measurements will be combined with a stable isotope tracer infusion to measure muscle glucose uptake and amino acid balance, uptake, and efflux.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with Type 2 Diabetes | Experimental | Two days of standardized meal consumption |
|
| Participants without Type 2 Diabetes | Experimental | Two days of standardized meal consumption |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Forearm immobilization | Behavioral | Two days of forearm immobilization |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in forearm muscle glucose uptake | The change in postprandial muscle insulin sensitivity, measured as forearm glucose uptake, from pre-immobilization to post-immobilization | From 0 to 48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Temporal change in forearm glucose uptake | The change in postprandial muscle insulin sensitivity, measured as the temporal response of forearm glucose uptake (FGU), in response to repeated meals during 48 hours of forearm immobilization | Prior to and for 3.5 hours following every meal consumption during the 48 hours forearm immobilization period |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marlou Dirks, PhD | Contact | +31 317 480 100 | marlou.dirks@wur.nl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wageningen University and Research | Recruiting | Wageningen | Gelderland | 6708WD | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in forearm muscle amino acid kinetics | Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the rate of appearance (Ra) of phenylalanine across the forearm. | Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours) |
| Change in forearm muscle amino acid kinetics | Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the rate of disappearance (Rd) of phenylalanine across the forearm. | Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours) |
| Change in forearm muscle amino acid kinetics | Plasma phenylalanine kinetics assessed using a stable isotope tracer infusion. Measurements include the net balance (NB) of phenylalanine across the forearm. | Baseline and at regular intervals for 3.5 hours following the first and last meal consumption during the test period (0 to 48 hours) |
| Change in whole-body substrate oxidation | Change in whole-body substrate oxidation measured using indirect calorimetry, measured before and in response to repeated mixed meals | Measurements will be performed at baseline, and at postprandial intervals (at 1 hour, 2 hours, 3 hours) during a 0 to 48-hour test period. |
| D004700 | Endocrine System Diseases |